Bayh-Dole Reform and the Progress of Biomedicine
The content you've requested is available without charge only to active Sigma Xi members and affiliates.
If you are an active member, affiliate or individual subscriber, please log in now in order to access this article. Be sure you've entered your member or subscriber number on your profile page. (You can access your profile page through the green box to the right.)
If you are not a member, affiliate or individual subscriber, you can:
The Bayh-Dole Act of 1980 allowed universities to patent (and then to license) discoveries made in the course of government-sponsored research. The Act was meant to promote the commercialization of this research, which, it was thought, might otherwise languish for lack of proponents with a strong financial interest. Yet many cases the law actually thwarts the dissemination of publicly sponsored science by allowing the patent system to encroach on areas of basic research that were formerly the domain of open scholarly exchange. Hence the law merits modification, at least in how it applies to biopharmaceutical research, so as to give funding agencies greater latitude in controlling the proprietary claims of their grantees.